Technology
Extracellular matrix (ECM) preservation technology.
Imagine in the future: altering one's biology to quickly repair a tear (ACL, shoulder, bicep, etc)
Imagine in the future: eliminating back and joint pain
Imagine in the future: rejuvenating tissues and extending lifespan by restoring function
Imagine in the future: recovering rapidly post-surgery with reduced pain and scarring
Our Approach to Biological Science
As tissue ages, the body’s natural repair and remodeling capacity decreases, causing a decline in structural integrity due to a lack of intact native tissue framework. Employing innovative science, Skye evaluates native biological platforms designed to decipher and support the natural repair process, promoting structural integrity and optimal matrix integration.
Our approach explores naturally advanced human biological material, studying complex native structural components to provide homologous support across a range of surgical and non-surgical specialties—including orthopedics, spine, sports medicine, wound administration, and soft tissue applications. By researching and evaluating these versatile tissue platforms, Skye aims to expand structural options that support patient recovery and quality of life across high-unmet-need clinical areas.
Pipeline
Medicines with breakaway potential.
Products
Industry leading unique tissue transplants.
Who we are
Tackling a current $100+ billion healthcare spend, Skye is rapidly advancing multiple future regenerative biological therapies that will target all areas both surgically and non-surgically of the musculoskeletal system, internal tissue structures and areas where there is a high-unmet medical need by leveraging its platform and expertise. One of the goals is that the therapies in development will reduce the historically high cost of treatment in our healthcare system with better patient outcomes. We are dedicated and strive to accelerate to market regenerative solutions that dramatically improve people's lives and longevity. A biotech leader since 2010, Skye has grown to be one of the world's leading independent new age biotechnology companies, has reached hundreds of thousands of patients in the US with existing tissue products and is developing a pipeline of medicines with breakaway potential for decades to come.
